What are the medication instructions for ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib is a highly effective oral anti-cancer drug that is widely used in the treatment of various cancers such as chronic lymphocytic leukemia. To ensure treatment effectiveness and patient safety, correct medication administration is crucial.

For the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenstrom's macroglobulinemia (WM), the recommended dose of ibrutinib is 420 mg daily, which should be continued until disease progression or intolerable toxicity occurs. For patients with chronic graft-versus-host disease (cGVHD), the recommended dose for patients 12 years of age and older is 420 mg daily, while patients 1 to 12 years of age should receive 240 mg/m2 daily based on body surface area (up to a maximum of 420 mg) until disease progression, recurrence of underlying malignancy, or unacceptable toxicity. When cGVHD treatment is no longer needed, it should be discontinued gradually based on the patient's specific condition.

If patients need to take other drugs at the same time, they should inform their doctor to avoid possible drug interactions or adverse reactions. In the treatment of CLL/SLL, ibrutinib can be used as a single agent or in combination with rituximab, obinutuzumab and other drugs; for WM, it can be used alone or in combination with rituximab. Patients should try to take ibrutinib at the same time each day, taking the tablet or capsule with a glass of water, making sure to swallow the tablet whole without chewing or opening the capsule. If you miss a dose, you should take it as soon as possible on the same day and resume the normal dose time the next day. It is important not to take extra medication to make up for a missed dose.